A systematic approach to the selection of the appropriate avibactam concentration for use with ceftazidime in broth microdilution susceptibility testing.
A systematic approach to the selection of the appropriate avibactam concentration for use with ceftazidime in broth microdilution susceptibility testing. by Bradford PA, Huband MD and Stone GG published in Antimicrob. Agents Chemother.: in press, 2018.
Antimicrobial susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa isolates from United States medical centers stratified by infection type: Results from the International Network for Optimal Resistance Monitoring (INFORM) surveillance program, 2015-2016.
Antimicrobial susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa isolates from United States medical centers stratified by infection type: Results from the International Network for Optimal Resistance Monitoring (INFORM) surveillance program, 2015-2016. by Sader HS, Castanheira M, Duncan LR and Flamm RK published in Diagn. Microbiol. Infect. Dis. 2018: 92 (1); 69-74
Cefepime-AAI101 and cefepime MIC quality control ranges using a CLSI M23-A5 multi-laboratory study design.
Cefepime-AAI101 and cefepime MIC quality control ranges using a CLSI M23-A5 multi-laboratory study design. Lead author: MD Huband, presented at 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P2492
Antimicrobial activity of ceftolozane-tazobactam tested against contemporary (2012-2017) Gram-negative isolates from patients hospitalised with pneumonia in European medical centres.
Antimicrobial activity of ceftolozane-tazobactam tested against contemporary (2012-2017) Gram-negative isolates from patients hospitalised with pneumonia in European medical centres. Lead author: D Shortridge, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P2432
Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from paediatric patients in Europe during 2012-2017 as part of a global surveillance program.
Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from paediatric patients in Europe during 2012-2017 as part of a global surveillance program. Lead author: D Shortridge, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P2434
Antimicrobial activity of ceftolozane-tazobactam tested against contemporary (2012-2017) P. aeruginosa isolates from hospitalised patients in European medical centres.
Antimicrobial activity of ceftolozane-tazobactam tested against contemporary (2012-2017) P. aeruginosa isolates from hospitalised patients in European medical centres. Lead author: D Shortridge, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P2431
Antimicrobial activity of murepavadin tested against clinical isolates of Pseudomonas aeruginosa collected in Europe, United States and China.
Antimicrobial activity of murepavadin tested against clinical isolates of Pseudomonas aeruginosa collected in Europe, United States and China. Lead author: HS Sader, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, Madrid, Spain
# P1662
Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalised with community-acquired bacterial pneumonia: Evaluation of ceftaroline potency and antimicrobial spectrum.
Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalised with community-acquired bacterial pneumonia: Evaluation of ceftaroline potency and antimicrobial spectrum. Lead author: HS Sader presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1817
Community-acquired skin and soft tissue infection in Europe, Asia and Latin America: Frequency of organism occurrence and antimicrobial activity of ceftaroline and comparator agents.
Community-acquired skin and soft tissue infection in Europe, Asia and Latin America: Frequency of organism occurrence and antimicrobial activity of ceftaroline and comparator agents. Lead author: HS Sader, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1805
In vitro activity of omadacycline and comparators against Gram-positive and -negative clinical isolates (including resistant organism subsets) collected in 2017 from patients in European medical centres: SENTRY Surveillance Program results.
In vitro activity of omadacycline and comparators against Gram-positive and -negative clinical isolates (including resistant organism subsets) collected in 2017 from patients in European medical centres: SENTRY Surveillance Program results. Lead author: MD Huband, presented in European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1822
Evaluation of tedizolid activity against Gram-positive clinical isolates causing pneumonia in Europe and surrounding areas (2017-2017).
Evaluation of tedizolid activity against Gram-positive clinical isolates causing pneumonia in Europe and surrounding areas (2017-2017). Lead author: RE Mendes, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1807
Murepavadin activity tested against contemporary (2016-2017) clinical isolates of extensively drug-resistant (XDR) Pseudomonas aeruginosa.
Murepavadin activity tested against contemporary (2016-2017) clinical isolates of extensively drug-resistant (XDR) Pseudomonas aeruginosa. Lead author: HS Sader, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, Madrid, Spain
# P1661
Antimicrobial activity of ceftazidime and piperacillin-tazobactam tested in combination with a potentiator molecule (SPR741) against Enterobacteriaceae causing urinary tract infections.
Antimicrobial activity of ceftazidime and piperacillin-tazobactam tested in combination with a potentiator molecule (SPR741) against Enterobacteriaceae causing urinary tract infections. Lead author: RE Mendes, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1671
Evaluation of synergistic effects of a potentiator molecule (SPR741) when tested in combination with a series of β-lactam agents against a challenge set of Gram-negative pathogens.
Evaluation of synergistic effects of a potentiator molecule (SPR741) when tested in combination with a series of β-lactam agents against a challenge set of Gram-negative pathogens. Lead author: RE Mendes, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1672
Activity of telavancin against a global collection of multidrug-resistant Gram-positive isolates and ceftaroline-nonsusceptible Staphylococcus aureus (2015-2017).
Activity of telavancin against a global collection of multidrug-resistant Gram-positive isolates and ceftaroline-nonsusceptible Staphylococcus aureus (2015-2017). Lead author: LR Duncan, presented at the 28th European Congress of Clinical Microbiology and Infections Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1808
Current in vitro analysis of tedizolid activity against Gram-positive clinical isolates causing bloodstream infections in Europe and surrounding areas (2014-2017).
Current in vitro analysis of tedizolid activity against Gram-positive clinical isolates causing bloodstream infections in Europe and surrounding areas (2014-2017). Lead author: RE Mendes, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1806
Geographic and temporal patterns of antimicrobial resistance in Pseudomonas aeruginosa from the SENTRY Surveillance Program, 1997-2016.
Geographic and temporal patterns of antimicrobial resistance in Pseudomonas aeruginosa from the SENTRY Surveillance Program, 1997-2016. Lead author: D Shortridge, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1140
Geographic and temporal variation on the frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalised with bacterial pneumonia: Results from 20 years of the SENTRY Program (1997-2016).
Geographic and temporal variation on the frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalised with bacterial pneumonia: Results from 20 years of the SENTRY Program (1997-2016). Lead author: HS Sader, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P0929
The worldwide panorama of Acinetobacter baumannii group and Stenotrophomonas maltophilia in the last 20 years: Results from the SENTRY Antimicrobial Surveillance Program (1997-2016).
The worldwide panorama of Acinetobacter baumannii group and Stenotrophomonas maltophilia in the last 20 years: Results from the SENTRY Antimicrobial Surveillance Program (1997-2016). Lead author: AC Gales, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1104
Changes in serotype distribution and antimicrobial nonsusceptibility in Streptococcus pneumoniae causing pneumonia in adults from 4 European countries following paediatric immunization with 13-valent pneumococcal conjugate vaccine (PCV13).
Changes in serotype distribution and antimicrobial nonsusceptibility in Streptococcus pneumoniae causing pneumonia in adults from 4 European countries following paediatric immunization with 13-valent pneumococcal conjugate vaccine (PCV13). Lead author: RE Mendes, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 21-24, Madrid, Spain
# P0606
In vitro evaluation of delafloxacin activity when tested against contemporary European community-acquired bacterial respiratory tract infection isolates (2014-2017): results from the SENTRY Antimicrobial Surveillance Program.
In vitro evaluation of delafloxacin activity when tested against contemporary European community-acquired bacterial respiratory tract infection isolates (2014-2017): results from the SENTRY Antimicrobial Surveillance Program. Lead author: D Shortridge, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P0599
Variations in the occurrence of ESBL, CRE and MDR phenotypes among Enterobacteriaceae isolates: Results from 20 years of the SENTRY Antimicrobial Surveillance Program.
Variations in the occurrence of ESBL, CRE and MDR phenotypes among Enterobacteriaceae isolates: Results from 20 years of the SENTRY Antimicrobial Surveillance Program. Lead author: M Castanheira, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1073
Activity of meropenem-vaborbactam against Enterobacteriaceae isolates collected during 2016.
Activity of meropenem-vaborbactam against Enterobacteriaceae isolates collected during 2016. Lead author: M Castanheira, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1043
Antimicrobial activity of omadacycline tested against clinical bacterial isolates collected from hospitals in China, including Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013-2016).
Antimicrobial activity of omadacycline tested against clinical bacterial isolates collected from hospitals in China, including Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013-2016). Lead author HS Sader, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P0102
Disk content assessment and proposed breakpoint interpretive criteria for cefepime in combination with AAI101.
Disk content assessment and proposed breakpoint interpretive criteria for cefepime in combination with AAI101. Lead author: MD Huband, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
#P0157
Twenty years of the SENTRY Antifungal Surveillance Program: Results for Candida species from 1997-2016.
Twenty years of the SENTRY Antifungal Surveillance Program: Results for Candida species from 1997-2016. Lead author: MA Pfaller, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P0323
Plazomicin activity against Enterobacteriaceae collected from Europe, Latin America, and Asia-Pacific during 2016, including those with aminoglycoside and beta-lactam resistance mechanisms.
Plazomicin activity against Enterobacteriaceae collected from Europe, Latin America, and Asia-Pacific during 2016, including those with aminoglycoside and beta-lactam resistance mechanisms. Lead author: M Castanheira presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P0093
Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015).
Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015). by Pfaller MA, Flamm RK, Duncan LR, Streit JM, Castanheira M and Sader HS published in Diagn. Microbiol. Infect. Dis. 2018; 91 (1): 77-84
Assessment of ceftazidime-avibactam 30/20 µg disk content versus MIC results when tested against Enterobacteriaceae and Pseudomonas aeruginosa.
Assessment of ceftazidime-avibactam 30/20 µg disk content versus MIC results when tested against Enterobacteriaceae and Pseudomonas aeruginosa. by Sader HS, Rhomberg PR, Huband MD, Critchley IA, Stone GG, Flamm RK and Jones RN published in J. Clin. Microbiol. 2018 in press
Dalbavancin in vitro activity obtained against gram-positive clinical isolates causing bone and joint infections in United States and European hospitals (2011-2016).
Dalbavancin in vitro activity obtained against gram-positive clinical isolates causing bone and joint infections in United States and European hospitals (2011-2016). by Pfaller MA, Flamm RK, Castanheira M, Sader HS and Mendes RE published in Int. J. Antimicrob. Agents. 2018; 51 (4): 608-611
Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016.
Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016. by Pfaller MA, Huband MD, Shortridge D and Flamm RK published in Antimicrob. Agents Chemother. 2018; 62 (4): e02327
Activity of omadacycline tested against Enterobacteriaceae causing urinary tract infections from a global surveillance program (2014).
Activity of omadacycline tested against Enterobacteriaceae causing urinary tract infections from a global surveillance program (2014). by Pfaller MA, Rhomberg PR, Huband MD and Flamm RK published in Diagn. Microbiol. Infect. Dis. 2018 in press
Fungemia surveillance in Denmark demonstrates emergence of Candida non-albicans, higher antifungal usage and resistance rates when compared to other nations.
Fungemia surveillance in Denmark demonstrates emergence of Candida non-albicans, higher antifungal usage and resistance rates when compared to other nations. by Castanheira M published in J. Clin. Microbiol. 2018; 56 (4): e01907
Activity of ceftolozane-tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates collected from respiratory tract specimens of hospitalized patients in the United States during 2013 to 2015.
Activity of ceftolozane-tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates collected from respiratory tract specimens of hospitalized patients in the United States during 2013 to 2015. by Castanheira M, Duncan LR, Mendes RE, Sader HS and Shortridge D published in Antimicrob. Agents Chemother. 2018; 62 (3): e02125
Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016).
Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016). by Pfaller MA, Huband MD, Streit J, Flamm RK and Sader HS Int. J. Antimicrob. Agents 2018; 51 (6): 848-853
In vitro activity of meropenem-vaborbactam and characterization of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem-vaborbactam surveillance program.
In vitro activity of meropenem-vaborbactam and characterization of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem-vaborbactam surveillance program. by Pfaller MA, Huband MD, Mendes RE, Flamm RK and Castanheira M. Int. J. Antimicrob. Agents. 2018: 52 (2); 144-150
In vitro activities of ceftaroline and comparators against Streptococcus pneumoniae isolates from U.S. hospitals: Results from seven years of the AWARE Surveillance Program (2010 to 2016).
In vitro activities of ceftaroline and comparators against Streptococcus pneumoniae isolates from U.S. hospitals: Results from seven years of the AWARE Surveillance Program (2010 to 2016). by Pfaller MA, Mendes RE, Duncan LR, Flamm RK and Sader HS published in Antimicrob. Agents Chemother. 2018 62 (2): e01555
In vitro activity of meropenem-vaborbactam and characterization of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem-vaborbactam surveillance program.
In vitro activity of meropenem-vaborbactam and characterization of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem-vaborbactam surveillance program. by Pfaller MA, Huband MD, Mendes RE, Flamm RK and Castanheira M publishedin Int. J. Antimicrob. Agents 2018 in press
Antimicrobial activity of dalbavancin against Staphylococcus aureus with decreased susceptibility to flycopeptides, daptomycin, and/or linezolid from U.S. Medical Centers.
Antimicrobial activity of dalbavancin against Staphylococcus aureus with decreased susceptibility to flycopeptides, daptomycin, and/or linezolid from U.S. Medical Centers. by Sader HS, Mendes RE, Duncan LR, Pfaller MA and Flamm RK published in Antimicrob. Agents Chemother. 2018; 62 (3): e02397
The application of in vitro surveillance data for antibacterial dose selection.
The application of in vitro surveillance data for antibacterial dose selection. by Flamm RK, Sader HS, Castanheira M and Jones RN published in Curr Opin Pharmacol 2017; 36:130-138
Antimicrobial activities of aztreonam-avibactam and comparator agents tested against contemporary (2016) clinical Enterobacteriaceae isolates.
Antimicrobial activities of aztreonam-avibactam and comparator agents tested against contemporary (2016) clinical Enterobacteriaceae isolates. by Sader HS, Mendes RE, Pfaller MA, Shortridge D, Flamm RK and Castanheira M published in Antimicrob. Agents Chemother. 2017; 62 (1): e01856
Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2013-2016) as part of the surveillance program: Program to Assess Ceftolozane-Tazobactam Susceptibility.
Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2013-2016) as part of the surveillance program: Program to Assess Ceftolozane-Tazobactam Susceptibility. by Shortridge D, Pfaller MA, Castanheira M and Flamm RK published in Microb. Drug Resist. 2018; 24 (5): 563-577
Antimicrobial activity of ceftazidime-avibactam tested against multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa isolates from United States medical centers (2013-2016).
Antimicrobial activity of ceftazidime-avibactam tested against multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa isolates from United States medical centers (2013-2016). by Sader HS, Castanheira M, Shortridge D, Mendes RE and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (11): e01045
Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: Report from an Antimicrobial Surveillance Program (2013-2015).
Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: Report from an Antimicrobial Surveillance Program (2013-2015). by Pfaller MA, Shortridge D, Sader HS, Gales A, Castanheira M and Flamm RK published in Braz. J. Infect. Dis. 2017; 21 (6): 627-637
Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing health care-associated infections in the Asia-Pacific region (APAC; minus China, Australia and New Zealand): Report from an antimicrobial surveillance program (2013-2015).
Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing health care-associated infections in the Asia-Pacific region (APAC; minus China, Australia and New Zealand): Report from an antimicrobial surveillance program (2013-2015). by Pfaller MA, Shortridge D, Sader HS, Castanheira M and Flamm RK Int. J. Antimicrob. Agents. 2018; 51 (2): 181-189
Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014).
Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014). by Pfaller MA, Rhomberg PR, Huband MD and Flamm RK published in Diagn. Microbiol. Infect. Dis. 2018; 90 (2): 143-147
Case report of transient mcr-1-haboring Escherichia coli with concurrent Staphylococcus aureus bacteremia in Long Beach, California.
Case report of transient mcr-1-haboring Escherichia coli with concurrent Staphylococcus aureus bacteremia in Long Beach, California. by Le J, Turner N, Deshpande LM, Davis AP and Castanheira M published in Diagn. Microbiol. Infect. Dis. 2017; 89 (4): 303-304
In vitro activity of the novel lactone ketolide nafithromycin (WCK 4873) when tested against contemporary clinical bacteria from a global surveillance program.
In vitro activity of the novel lactone ketolide nafithromycin (WCK 4873) when tested against contemporary clinical bacteria from a global surveillance program. by Flamm RK, Rhomberg PR and Sader HS published in Antimicrob. Agents Chemother. 2017; 61 (12): e01230
Dilution factor of quantitative bacterial cultures obtained by bronchoalveolar lavage in patients with ventilator-associated bacterial pneumonia: Implications for optimal antimicrobial therapy ventilator-associated bacterial pneumonia study group.
Dilution factor of quantitative bacterial cultures obtained by bronchoalveolar lavage in patients with ventilator-associated bacterial pneumonia: Implications for optimal antimicrobial therapy ventilator-associated bacterial pneumonia study group. by Drusano GL, Corrado ML, Girardi G, Ellis-Grosse EJ, Wunderink RG, Donnelly H, Leeper KV, Brown M, Malek T, Hite RD, Ferrari M, Djureinovic D, Kollef MH, Mayfield L, Doyle A, Chastre J, Combes A, Walsh TJ, Dorizas K, Alnuaimat H, Morgan BE, Rello J, Mazo Torre CA, Jones RN, Flamm RK, Woosley L, Ambrose PG, Bhavnani S, Rubino CM, Bulik CC, Louie A, Vicchiarelli M and Berman C published in Antimicrob. Agents Chemother. 2018; in press
Enhanced activity of cefepime-tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride.
Enhanced activity of cefepime-tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride. by Castanheira M, Duncan LR, Rhomberg PR and Sader HS published in Diagn. Microbiol. Infect. Dis.2017; 89 (4): 305-309
